Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study

BACKGROUND: Prokinetics are used to treat enteric dismotility symptoms in systemic sclerosis (SSc) patients, but they often lack adequate efficacy. The most effective prokinetics belonging to the serotonin (5-HT(4)) receptor agonists class were withdrawn due to cardiac toxicity in relation to modest...

Descripción completa

Detalles Bibliográficos
Autores principales: Vigone, Barbara, Caronni, Monica, Severino, Adriana, Bellocchi, Chiara, Baldassarri, Anna Rita, Fraquelli, Mirella, Montanelli, Gaia, Santaniello, Alessandro, Beretta, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477745/
https://www.ncbi.nlm.nih.gov/pubmed/28633671
http://dx.doi.org/10.1186/s13075-017-1340-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477745/
https://www.ncbi.nlm.nih.gov/pubmed/28633671
http://dx.doi.org/10.1186/s13075-017-1340-y

Ejemplares similares